Pharmaceutical company SOHM has acquired ABBIE, a gene-editing platform, for USD 10 million from cell biotech company CGA 369.
The acquisition marks SOHM’s entry into the gene-editing market, which is expected to reach USD 10.8 billion by 2028. ABBIE is currently under development, and it is expected to reach in-human trials by the end of 2025. The acquisition will enable SOHM to generate revenue through licensing and the release of gene-editing kits. Additionally, ABBIE will also help SOHM tap into the global biotechnology kit market.
ABBIE is a gene-editing platform that can deliver genetic payloads using non-viral vectors. It uses targeted integration to insert larger DNA sequences into target cells' genomes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.